AstraZeneca PLC (AZN)vsVSee Health, Inc. (VSEE)
AZN
AstraZeneca PLC
$160.17
+2.25%
HEALTHCARE · Cap: $252.33B
VSEE
VSee Health, Inc.
$0.01
-6.67%
HEALTHCARE · Cap: $906,880
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 388130% more annual revenue ($61.37B vs $15.81M). AZN leads profitability with a 17.0% profit margin vs -62.6%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
VSEE
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Revenue surging 48.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -258.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : VSEE
The strongest argument for VSEE centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 48.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while VSEE is a hypergrowth play — different risk/reward profiles.
VSEE carries more volatility with a beta of 0.40 — expect wider price swings.
VSEE is growing revenue faster at 48.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 41/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a leading innovator in the telehealth sector, providing secure video communication solutions tailored for healthcare providers and patients alike. Its comprehensive platform enhances care delivery through features such as remote patient monitoring, asynchronous messaging, and seamless EMR integration, thereby bolstering efficiency and quality across various medical disciplines. As the demand for virtual care surges in the evolving healthcare landscape, VSee's commitment to patient engagement and accessibility positions it strategically for significant growth. With a focus on innovation and client success, VSee Health is well-prepared to capitalize on the expanding digital healthcare market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?